Single-Amino-Acid Substitutions in Open Reading Frame (ORF) 1b-nsp14 and ORF 2a Proteins of the Coronavirus Mouse Hepatitis Virus Are Attenuating in Mice by Sperry, Steven M. et al.
JOURNAL OF VIROLOGY, Mar. 2005, p. 3391–3400 Vol. 79, No. 6
0022-538X/05/$08.000 doi:10.1128/JVI.79.6.3391–3400.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Single-Amino-Acid Substitutions in Open Reading Frame (ORF)
1b-nsp14 and ORF 2a Proteins of the Coronavirus Mouse
Hepatitis Virus Are Attenuating in Mice
Steven M. Sperry,1,2 Lubna Kazi,3 Rachel L. Graham,2,4 Ralph S. Baric,5 Susan R. Weiss,3
and Mark R. Denison1,2,4*
Departments of Pediatrics1 and Microbiology and Immunology4 and Elizabeth B. Lamb Center for Pediatric Research,2
Vanderbilt University Medical Center, Nashville, Tennessee; Department of Microbiology, University of Pennsylvania
School of Medicine, Philadelphia, Pennsylvania3; and Department of Epidemiology, School of Public Health,
University of North Carolina, Chapel Hill, North Carolina5
Received 27 August 2004/Accepted 1 November 2004
A reverse genetic system was recently established for the coronavirus mouse hepatitis virus strain A59
(MHV-A59), in which cDNA fragments of the RNA genome are assembled in vitro into a full-length genome
cDNA, followed by electroporation of in vitro-transcribed genome RNA into cells with recovery of viable virus.
The “in vitro-assembled” wild-type MHV-A59 virus (icMHV-A59) demonstrated replication identical to labo-
ratory strains of MHV-A59 in tissue culture; however, icMHV-A59 was avirulent following intracranial inoc-
ulation of C57BL/6 mice. Sequencing of the cloned genome cDNA fragments identified two single-nucleotide
mutations in cloned genome fragment F, encoding a Tyr6398His substitution in open reading frame (ORF) 1b
p59-nsp14 and a Leu94Pro substitution in the ORF 2a 30-kDa protein. The mutations were repaired individ-
ually and together in recombinant viruses, all of which demonstrated wild-type replication in tissue culture.
Following intracranial inoculation of mice, the viruses encoding Tyr6398His/Leu94Pro substitutions and the
Tyr6398His substitution alone demonstrated log10 50% lethal dose (LD50) values too great to be measured. The
Leu94Pro mutant virus had reduced but measurable log10 LD50, and the “corrected” Tyr6398/Leu94 virus had
a log10 LD50 identical to wild-type MHV-A59. The experiments have defined residues in ORF 1b and ORF 2a
that attenuate virus replication and virulence in mice but do not affect in vitro replication. The results suggest
that these proteins serve roles in pathogenesis or virus survival in vivo distinct from functions in virus
replication. The study also demonstrates the usefulness of the reverse genetic system to confirm the role of
residues or proteins in coronavirus replication and pathogenesis.
Mouse hepatitis virus (MHV) is a widely studied model
system for coronavirus replication and pathogenesis. Many
strains of MHV have been isolated which differ in their tissue
tropism and virulence. MHV strain A59 (MHV-A59) causes
hepatitis in mice, but following intracranial inoculation is also
capable of causing meningoencephalitis and chronic demyeli-
nating disease (20). There have been many studies demonstrat-
ing the role of the structural proteins and nonstructural group-
specific genes in replication and virulence, but only recently
have genetic approaches been available to study viral determi-
nants. Nevertheless, the complexity of coronavirus gene prod-
ucts makes it likely that new functions in replication and patho-
genesis will be identified in the genome, including the replicase
gene.
MHV possesses the largest positive-strand RNA genome of
any known virus at 32 kb (Fig. 1). The 5 two-thirds of the
genome encodes the replicase in two overlapping open reading
frames (ORFs), 1a and 1b, which, if translated in their entirety
by a 1 ribosomal frameshifting mechanism, generate a 800-
kDa polyprotein. The nascent replicase polyprotein is pro-
cessed by virus-encoded proteinases to yield intermediate pre-
cursor and 16 mature cleavage products, including three
proteinase activities, an RNA helicase/NTPase, and a putative
RNA-dependent RNA polymerase.
Recent bioinformatics studies suggested homology of the
3-most ORF 1b protein products, p59, p42, and p33 (nsp 14 to
16) to known cellular RNA processing enzymes. These include
a 3-5 exonuclease of the DEDD superfamily for nsp14-p59, a
poly(U)-specific endoribonuclease for nsp15-p42, and an S-
adenosylmethionine-dependent ribose 2-O-methyltransferase
of the RrmJ family for p33 (43). These ORF 1b-encoded pro-
teins have high primary amino acid sequence identity among
all sequenced coronaviruses. Endonuclease activity has been
demonstrated for recombinant purified poly(U)-specific en-
doribonuclease (16).
During MHV-A59 infection, six subgenomic mRNAs are
transcribed from the 3 9.5 kb of the genome. These sub-
genomic mRNAs encode the structural proteins of MHV, in-
cluding the spike glycoprotein (S), membrane protein (M),
small membrane protein (E), and the nucleocapsid protein
(N). Several other small open reading frames encode addi-
tional nonstructural proteins of largely unconfirmed function.
These ORFs are referred to as “group-specific” ORFs because
they are generally conserved in viruses in the same group in
their sequence and expression but differ across groups. The
MHV mRNA2 is translated to yield the ORF 2a protein, a
30-kDa nonstructural protein that was recently predicted,
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based on conservation of specific residues, to be a cyclic phos-
phodiesterase, an RNA processing enzyme involved in tRNA
maturation pathways (43).
Until recently, reverse genetics studies of MHV were per-
formed exclusively with targeted recombination (18). This sys-
tem remains a powerful and flexible system; however, it does
not allow targeted mutagenesis of the 5 20 kb of the MHV
genome, which comprises the replicase gene, since the recom-
bination donor is an RNA molecule containing the 3 10 kb
of the genome. A new reverse genetics system for MHV-A59
was recently described by Yount et al. that allows targeting of
mutations to any portion of the genome but specifically to the
replicase and the 5 noncoding region of the genome (50). This
reverse genetics approach divides the genome into seven
cDNA fragments (A to G), which are ligated in vitro and
transcribed in vitro into full-length infectious RNA genome,
which is then electroporated into cells with recovery of recom-
binant virus. The recombinant wild-type infectious clone
MHV-A59 (icMHV-A59) obtained from this approach is iden-
tical to laboratory strains of MHV-A59 in replication, protein
processing, and genomic and subgenomic RNA synthesis in
tissue culture (50). The cloned fragments have been mutated
to introduce substitutions and deletions in the replicase
polyprotein, with defined changes in protein processing and
virus replication (11).
In the current study we initially sought to confirm the viru-
lence of wild-type icMHV-A59 in mice, since it demonstrated
wild-type replication in culture. Surprisingly, pilot studies with
intracranial inoculation of C57BL/6 mice showed that wild-
type icMHV-A59 caused only mild illness and no deaths, even
at inoculation doses 100 times greater than that causing mor-
tality with wild-type MHV-A59. Sequencing of the genome
cDNA fragments A through G identified two single-nucleotide
mutations resulting in amino acid substitutions, one in the
replicase ORF 1b p59-nsp14 protein (Tyr6398His) and the
other in the ORF 2a 30-kDa protein (Leu94Pro). Repair of the
residues to the conserved consensus sequence restored viru-
lence in mice to that of wild-type A59. Viruses retaining either
or both substitutions were independently attenuated for viru-
lence in mice while demonstrating replication in culture iden-
tical to wild-type MHV-A59. The attenuated mutants had de-
creased virus titers in mouse brains, with evidence in some
mice of partial or complete reversion of the residues to the
consensus wild-type sequence. The experiments have identified
residues in the replicase and in the ORF 2a protein at which
substitutions do not impact replication in culture but may be
critical for virus survival and virulence in vivo. Further, the
studies have resulted in a stably cloned consensus MHV ge-
nome with a completely characterized sequence that directs
synthesis of virus with both wild-type replication in culture and
virulence in animals.
MATERIALS AND METHODS
Viruses and cells. Delayed brain tumor (DBT) cells and baby hamster kidney
cells expressing the MHV receptor (BHK-MHVR) were grown in Dulbecco’s
modified Eagle’s medium containing 10% fetal calf serum. The BHK-MHVR
cells were grown under G418 selection (0.8 mg/ml), as previously described (11,
50). For comparisons of animal virulence, engineered viruses as described below
were compared with RA59, a recombinant wild-type MHV-A59 selected by
targeted recombination (32, 33). This RA59 virus therefore contains the same 3
10 kb as all viruses in this study, since they were similarly derived from the
pMH54 cloned sequence. In addition, RA59 has been shown to recapitulate the
virulence of laboratory strains of “wild-type” MHV-A59 (33).
Reverse genetic engineering and recovery of recombinant MHV-A59. The
reverse genetics system for MHV-A59 was used to generate engineered viruses
and to modify the genome, as previously described (11, 50). Plasmids containing
FIG. 1. MHV genome organization, proteins, and genome cDNA fragments. (A) The MHV reverse genetics system divides the genome into
seven cDNA fragments with a T7 promoter at the beginning of fragment A and poly(A) tail at the end of the fragment G (pMH54). The junction
of the fragments is indicated by nucleotide number. (B) The genome consists of seven genes. The replicase gene comprises the first 22 kb. Genes
2 to 7 are translated from subgenomic mRNA species (not shown). The relative locations of coding regions for the structural proteins S, E, M,
and N are shown, as is the coding region for the group-specific ORF 2a 30-kDa protein. (C) The ORF 1a and frameshifted ORF 1a/b fusion
polyproteins are depicted (pp1a and pp1ab, respectively). The protein domains of the replicase polyprotein are indicated by nonstructural protein
number (nsp1 to 16) and by confirmed or predicted functions: PLP1 and 2, papain-like proteinases; 3CLpro, 3C-like proteinase; Pol, putative
RNA-dependent RNA polymerase; Hel, helicase; ExoN, putative exonuclease; XendoU, putative poly(U)-specific endoribonuclease; 2-O-MT,
methyltransferase. Proteins with substitutions are shown as black rectangles.
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cDNA fragments A through G of the MHV RNA genome were digested, and the
gel-purified genome fragments were ligated in vitro to yield a full-length genome
cDNA. The T7 transcription promoter at the 5 end of fragment A was used to
drive transcription of full-length genome RNA, including a templated poly(A)
tail, with the mMessage mMachine T7 transcription kit (Ambion). A 50-l
reaction was assembled according to the manufacturer’s instructions, but for our
experiments was modified by supplementation with 7.5 l of 30 mM GTP, and
the transcription reaction was performed at 40.5°C for 25 min, 37.5°C for 50 min,
and 40.5°C for 25 min.
The full-length MHV genome transcripts were then combined with in vitro
transcripts of the viral nucleocapsid gene and 600 l of BHK-MHVR cells in
phosphate-buffered saline (107 cells/ml) in a 4-mm-gap cuvette, and three elec-
trical pulses of 850 V at 25 F were delivered to the mixture in a Bio-Rad Gene
Pulser Xcell electroporator. Electroporated cells were seeded over a layer of 106
uninfected DBT cells in a 75-cm2 flask and incubated at 37°C for 30 h. Virus
viability was determined by the appearance of cell death, plaques, and confluent
syncytium formation and by the recovery of infectious virus from medium su-
pernatant that was detectable by plaque assay and by infection of cell monolay-
ers. Recovered virus was maintained as population stocks following passage of
the medium from electroporated cells and also by selection of plaques followed
by amplification of plaqued clones as P1 stocks. The outcome is recovery of
engineered recombinant viruses with wild-type or mutant sequence. Since no
single term is adequately descriptive of the whole process, we will for this report
refer to the viruses as recombinant viruses and by reference to mutations, with
the understanding that all viruses were generated by the same process. The
nomenclature infectious clone will be retained for the original wild-type cloned
MHV (icMHV-A59) that is the basis for the studies in this report.
Sequencing MHV cDNA fragments. The infectious clone MHV cDNA frag-
ments (A to G) were sequenced with a set of primers designed from the MHV
genome (NCBI accession 1NC001846). Sequencing primers were created every
600 bp, beginning with the 5 end, from both the sense and antisense strands.
These primers generated overlapping sequences spanning the cDNA clones at
least twice and up to four times in targeted regions. The plasmid vectors and
cloned fragments A to G have been characterized previously, and further mod-
ifications to fragment F are reported below. The M13 forward and reverse
primers were used to sequence the insert-vector junction of fragments A, F, and
G, and primers SL1 and SR1 for the pSMART vector (Lucigen) were used for
fragments B to E.
Sequencing was performed with an ABI Prism automated sequencer. The
sequences were aligned and compared with MHV sequences from the NCBI
database: NC001846 (MHV-A59 mutant C12 genome); X73559 (24), X51939
(5), M23256 (25), M18379 (26), S58172 (47), M16602 (7), and X00509 (44)
(wild-type MHV-A59 sequences); M55148 (21) (MHV-JHM ORF 1a/b se-
quence); M57954 (37), M57953 (37), M28348 (41), and M34035 (37) (MHV-
JHM ORF 2a sequences); AF201929 (MHV-2 genome) (36); and AF207902 (8),
AF208066 (unpublished), and AF208067 (8) (MHV recombinant genomes).
Site-directed mutagenesis and repair of genome cDNA fragment F. Site-
directed mutations were made in fragment F (nucleotides 15755 through nucle-
otides 22740 from the 5 end of the MHV-A59 genome). Fragment F was
digested from the pCR-XL-Topo vectors originally employed and blunt ligated
into a restriction digested (KpnI and SacI) and filled in (T4 DNA polymerase)
pSMART-LC-Amp (Lucigen) vector in which the multiple cloning site from
pBluescript II KS (nucleotides 657 to 755) was inserted at the PCR cloning site
between nucleotides 2025 and 1 in the linear vector. Mutational repair of ic-
MHV-A59 genome nucleotide 19400 (C to T), nucleotide 22051 (C to T), or both
was accomplished by PCR with the primers shown in Table 1 and methods as
previously described (50). A 5 BstBI and 3 AflII site or a 5 AflII and 3 SpeI
site were used to clone the PCR product with the C19400T repair or C22051T
repair, respectively, into fragment F in the pSMART-LC vector. All mutations
were sequence confirmed and demonstrated stable growth and maintenance of
changes in Escherichia coli in this vector.
Reverse transcription-PCR and sequencing of viral RNA. For all sequencing
of genome RNA, discrete viral plaques under agar were selected during plaque
assays. Virus was aspirated from plaques, dispersed in 1 ml of gel saline, and used
to infect DBT cells in 25-cm2 flasks (3  106 cells) for 30 min, followed by
addition of Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum.
When80% of the monolayer was involved in syncytia (12 to 24 h postinfection),
the cells were lysed with Trizol reagent (Invitrogen) and total RNA was isolated
according to the manufacturer’s protocol.
An antisense primer complementary to nucleotides 22126 through 22144 of
the MHV genome was used to generate viral cDNA from the total RNA with
reverse transcription. The reverse transcription product was amplified by PCR
with the same antisense primer and a sense primer complementary to nucleotides
19321 through 19338. This PCR product was then sequenced over nucleotide
19400 and nucleotide 22051 to confirm the sequences of all viruses recovered
following electroporation and replication in culture or from the brains of infected
mice.
Virus replication in DBT cells. For analysis of replication, DBT cells in two
replicate 75-cm2 flasks (107 cells) were infected at a multiplicity of infection of
5 PFU/cell or 0.01 PFU/cell with passage 1 (P1) stocks of plaque isolates. Virus
was adsorbed for 30 min at room temperature with rocking, and cells were then
washed three times with phosphate-buffered saline (10 min per wash). Medium
was added, and the cells were incubated at 37°C. Samples of medium were
collected at 1, 4, 8, 12, 16, 25, 30, 36, and 42 h postinfection, and viral titers were
determined by plaque assay on DBT cells as described previously (17). For each
virus and time point, results presented are the mean of two independent repli-
cates and two measurements at each time point.
Inoculation of mice, virulence assays, and measurement of brain virus titers.
All animal experiments used 4-week-old MHV-free C57BL/6 mice (Jackson
Laboratory, Bar Harbor, Maine). Mice were anesthetized with isofluorane. For
intracranial inoculation, the amount of virus designated in each experiment was
diluted in phosphate-buffered saline containing 0.75% bovine serum albumin,
and a total volume of 20 l was injected into the left cerebral hemisphere.
Mock-infected controls were inoculated similarly but with an uninfected cell
supernatant at a comparable dilution.
Fifty percent lethal dose (LD50) assays were performed as previously described
(15). Mice were inoculated intracranially with three serial dilutions (103, 104, and
105 PFU) of plaque-purified RA59, wild-type icMHV-A59, or mutant virus
VUSS0, VUSS1, VUSS2, or VUSS3. In two independent experiments, a total of
5 to 15 animals per dilution per virus were analyzed. Mice were examined for
signs of disease or death on a daily basis for up to 21 days postinfection. LD50
values were calculated by the Reed-Muench method, as previously described
(28). For the measurement of virus replication in mouse brains and livers, 10
mice for each virus were infected with 5  103 PFU intracranially. Five mice for
each virus were sacrificed at day 5 and day 7 postinfection and perfused with 10
ml of phosphate-buffered saline, and the brains and livers were removed. Each
organ was placed directly into 2 ml of isotonic saline with 0.167% gelatin (gel
saline), weighed, and stored frozen at 80°C until virus titers were determined.
Organs were homogenized, and virus titers were determined by plaque assay on
DBT cell monolayers as previously described (15).
TABLE 1. Primers for mutagenesis of bases 19400 and 22051
Primer Sequencea Purpose
19400 BsmBI Left 5-CGTCTCG19397TTGTATGTTAACAAACATGCATTCCACACC119426 Mutagenesis primer nt 19400
19400 BsmBI Right 5-CGTCTCG19400ACAAACTGCCACCATTACAGCCAGG19376 Mutagenesis primer nt 19400
19400 Outer Left 5-18638GTGGTTCGAATTAGAATAGTACAAATGTTGTCAGACCACC18677 Sense primer BsmBI Right
19400 Outer Right 5-19944TTTCTAAAGAGCTTAAGCTCGGGGTGGGGCCGAATA19909 Antisense primer BsmBI Left
22051 BbsI Left 5GAAGACGC22048TTCTTGATGTTAGAGGATTTGAAGAGTTGCA22078 Mutagenesis primer nt 22051
22051 BbsI Right 5Q˜G GAAGACGC22051AGAACAAGGCATCTGCCAAGCATGTG22026 Mutagenesis primer nt 22051
22051 Outer Left 5Q˜19921CCCCGAGCTTAAGCTCTTTAGAAATTTGAATATTGACGTG19960 Sense primer BsmBI Right
22051 Outer Right 5Q˜G TCGGATCCACTAGTAACGGCCGCCAGTGTGCTGGAATT Antisense primer BsmBI Left
pSMART vector sequence
a Underlined nucleotides indicate restriction enzyme recognition sites. Nucleotides in bold-point mutations introduced into the VUSS0 sequence to restore
MHV-A59 consensus sequence. Subscript numbers indicate boundaries of genomic sequence.
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Viruses from brains were isolated from individual plaques, and their genomes
were sequenced in the regions encompassing the residues of interest with reverse
transcription-PCR as described in the previous section. Plaque isolates from
brains of two different mice per virus were sequenced across 600 nucleotides,
including the coding region for ORF 1a/b residue 6398 and ORF 2a residue 94
to confirm the sequences and identify any reversions or new mutations in flank-
ing sequences. For viruses where one or more plaque-cloned isolate demon-
strated changes from the input virus inoculum, virus plaque isolates from up to
five additional mice were sequenced.
Nucleotide sequence accession number. The GenBank accession number for
the VUSS3 virus described in this report is AY910861.
RESULTS
icMHV demonstrates wild-type replication in culture but is
attenuated in vivo. It has been shown that the original recom-
binant wild-type icMHV-A59 recovered following electropora-
tion of cells with genome RNA transcribed in vitro from as-
sembled full-length genome cDNA has wild-type replication in
cultured cells (11, 50). To determine the virulence of icMHV
in mice, 105 PFU of icMHV or RA59 was used to infect mice
by intracranial inoculation. RA59 is a recombinant virus ob-
tained by targeted recombination and serves as a control wild-
type virus (33). We chose this virus for comparison with re-
combinant wild-type icMHV-A59 since the pMH54 donor
plasmid was used for targeted recombination and was also the
sequence used to generate fragment G used in the in vitro
assembly of full-length genome cDNA (18, 50). Thus, both
RA59 and icMHV possess the identical 3 10 kb of sequence.
Viruses derived from targeted recombination with pMH54,
specifically RA59, have been shown to possess wild-type
growth and virulence following intracranial inoculation of mice
(33). However, in the pilot experiment, while some mice had
transient illness, no mice inoculated with recombinant wild-
type icMHV-A59, even at doses 100 times the LD50 of wild-
type A59, died. This surprising result suggested that new or
unrecognized changes in icMHV arising during its recovery or
passage in cells had resulted in loss of replication, virulence, or
both in animals. Alternatively, we considered the possibility
that new mutations introduced during propagation of the frag-
ment A through G plasmids in E. coli had resulted in changes
affecting virulence in animals. This lack of virulence was par-
ticularly surprising since multiple wild-type and mutant viruses
engineered on this background have demonstrated growth,
plaque, protein, and RNA phenotypes indistinguishable from
laboratory strains of MHV-A59. Thus, we hypothesized that
any changes in the virus genome would alter virulence in mice
but not affect replication in culture.
Identification of attenuating mutations in recombinant
wild-type icMHV-A59. To identify candidate mutations in wild-
type icMHV-A59 that might have contributed to this loss of
virulence, cloned genome cDNA fragments A through G
cDNAs were sequenced bidirectionally with overlapping sets
of primers, resulting in sequence covering the genome at least
twice and in some cases up to four times. The sequences were
then compared with the sequences of the original amplicons
and with published sequences (50).
Examination of key marker mutations in the sequence shows
that the lineage of the infectious clone genome is most similar
to MHV-A59 virus isolates derived from virus first described
by Sturman (23), in contrast to the MHV-A59 viruses from
which the majority of the published wild-type sequence frag-
ments were derived (2, 5–7, 25, 47). The cDNA fragment A to
G sequences were compared with the genome sequence of the
C12 mutant virus (23) (NCBI accession 1NC001846), which
also was derived from the Sturman lineage (15). Previous se-
quencing of the C12 mutant virus identified five coding muta-
tions, one silent mutation, and one mutation in an untranslated
region compared to the wild-type MHV-A59 sequences that
were distinct from variations in known virulent viruses (23).
The infectious clone fragment cDNA sequences did not con-
tain any of the seven mutations previously identified for the
C12 mutant virus.
We did identify 26 differences that either resulted in no
amino acid substitutions (silent) or were located in untrans-
lated regions of the genome. Three coding mutations were
identified in fragments A to G (Fig. 2A). Ten of the 26 silent
or untranslated mutations were previously reported as engi-
neered mutations in the cDNA fragments A to G to remove
restriction sites or create unique junctions (49). An additional
ten silent and one coding mutation were identified in fragment
G, which was derived from the pMH54 plasmid (19, 50). The
sequence of fragment G matched pMH54 with the exception of
one silent mutation (A23441G) in the nonexpressed ORF 2b
(HE) gene (sequence kindly provided by Paul Masters).
Since several studies have shown that viruses generated by
targeted recombination with pMH54 or a derivative are viru-
lent (9, 19, 33), we focused on the two novel mutations found
in the first 22.7 kb of the genome. When all previously de-
scribed mutations and consensus sequences were considered,
the cDNA sequences identified two single-nucleotide coding
mutations, both in fragment F, T19400C and T22051C. These
two mutations have not been described in any submitted or
published MHV-A59 sequences or in related MHV-2, MHV-
JHM, or recombinant virus sequences (2, 4, 8, 9, 22, 23, 25, 38,
42). Furthermore, the wild-type MHV-A59 viruses from the
Denison laboratory at Vanderbilt University and the Weiss
laboratory at the University of Pennsylvania were sequenced
by reverse transcription-PCR over these regions and found to
have T19400 and T22051 (not shown).
The first of these mutations predicted a Tyr6398His amino
acid substitution in the ORF 1ab polyprotein. The Tyr6398His
substitution is found in the sequence encoding MHV ORF 1b
p59-nsp14. The Tyr6398 residue is absolutely conserved for
coronaviruses with determined sequence (not shown). The sec-
ond mutation was a Leu94Pro amino acid substitution in the
ORF 2a 30-kDa protein. While only group 2 coronaviruses
encode the group-specific ORF 2a protein, within that group
the viruses that possess an intact ORF 2a protein have con-
served the Leu94 residue (not shown). Thus, sequencing of the
genome fragment cDNAs identified two novel coding muta-
tions at conserved residues that were candidates for attenua-
tion of the wild-type icMHV-A59 virus.
Correction of candidate attenuating mutations in wild-type
icMHV-A59. While it was formally possible that introduced or
identified changes at noncoding (silent) or nontranslated nu-
cleotides could account for the loss of virulence, we hypothe-
sized that coding changes were more likely to affect replication
or virulence. We restored the genome nucleotide sequences
individually and in combination to the consensus wild-type
sequences, C19400T and C22051T, both within fragment F,
with site-directed PCR mutagenesis. Following sequence con-
firmation of the changes, the corrected sequences encoded
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proteins with the wild-type residues Tyr6398 in ORF 1b p59-
nsp14 and Leu94 in the ORF 2a 30-kDa protein. The corrected
fragment F clones were used with fragments A, B, C, D, E, and
G to assemble full-length genome cDNA in vitro, transcribe
infectious genome RNA in vitro, electroporate cells, and re-
cover virus (Fig. 3B).
The genome encoding both the uncorrected His6398 and
Pro94 residues was designated VUSS0 to distinguish it from
the reported recombinant wild-type icMHV-A59 and because
of the probability that the changes were acquired after se-
quencing of the original fragments. VUSS1 encoded the cor-
rected Tyr6398 (ORF 1b p59-nsp14) and mutant Pro94 (ORF
2a 30-kDa protein). VUSS2 encoded the mutant His6398
(ORF 1b p59-nsp14) and repaired Leu94 (ORF 2a 30-kDa
protein). VUSS3 restored both consensus wild-type Tyr6398
and Leu94 residues. Recovered viruses were passaged three
times in culture, and the sequence of genome RNA of purified
virions was determined for both the population virus and
plaque-cloned isolates. The sequences of the cloned mutant
and repaired cDNA fragments were retained in the recovered
viruses in all cases with no evidence of heterogeneity or other
changes in the 3 kb incorporating both of the targeted nu-
cleotides (data not shown).
Uncorrected and corrected viruses exhibit wild-type repli-
cation in DBT cells. Single-cycle growth experiments were
performed to compare the replication of putative wild-type
and mutant viruses. When cells were infected at a multiplicity
of infection of 5 PFU/cell, VUSS0, VUSS1, VUSS2, and
VUSS3 all demonstrated peak titers, replication kinetics, cy-
topathic effect, and plaque morphology identical to wild-type
A59 and the original recombinant wild-type icMHV-A59 (Fig.
4).
To test the possibility that mutant viruses had subtle repli-
cation differences detectable only during multiple-cycle
growth, the growth assay was repeated with a multiplicity of
infection of 0.01 PFU/cell. In direct comparison of two repli-
cate infections for all viruses, the time to increase in virus titer
and achievement of peak titer was delayed by 4 to 8 h com-
pared with the high-multiplicity infection, confirming the mul-
tiple-cycle infection. However, as with the high-multiplicity
infection, the replication kinetics and peak titers were overlap-
FIG. 2. Mutations identified by sequencing of the genome cDNA fragments. Genome fragments A through G are shown. The sequence was
compared with published sequences as indicated in the text. The comparison identified 29 silent or nontranslated nucleotide differences (indicated
by circles; a single circle can indicate multiple clustered differences) at nucleotides G3518A, G3521C, T4874A, C4877G, T4970C, T7982C, T9305C,
A12962C, T12965A, C14014A, G17137A, G17140C, A17482G, T17524C, T19885C, A22608G, G22633T, T22739G, T22742C, C23393T, A23441G,
T23964C, T23965C, G24447A, C24448T, T24450A, T27915C, C27918G, and T27920A. Three coding nucleotide differences were identified
(indicated by squares) at nucleotides T19400C, T22051C, and T29650C. Ten of the silent mutations were engineered in the cloned fragments to
introduce unique junctions or remove restriction sites (grey circles). The fragment G cDNA was derived from the pMH54 vector (19), and
comparison of the sequences showed that of the eleven mutations identified, all had been previously noted (black circles and squares), except for
a single silent mutation at nucleotide 23441 in the untranslated hemagglutinin-esterase (HE) pseudogene. Two novel coding differences in the
cDNA fragments of the icMHV-A59 were identified at nucleotides 19400 and 22051 (white squares).
FIG. 3. Correction of substitution mutations in fragment F. (A)
Mutations were corrected at nucleotides 19400 and 22051, changing
the codons for amino acid 6398 in pp1a/b (amino acid 414 in p59-
nsp14) and amino acid 94 in ORF 2a 30-kDa protein. (B) Mutant
viruses were engineered with either a Tyr or His at amino acid residue
6398 in the ORF 1b p59-nsp14 paired with either a Leu or Pro at
amino acid 94 in the ORF 2a 30-kDa protein. Four viruses were
derived, representing the four possible combinations of amino acids at
the two sites.
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ping. While it is still possible that there are extremely subtle
alterations in replication, they are not detectable by our viro-
logical assays and suggest that in fact, replication in culture is
wild type in viruses with substitutions at ORF 1b p59-nsp14
Tyr6398 and ORF 2a 30-kDa protein Leu94.
Amino acid substitutions in the ORF 1b p59-nsp14 or ORF
2a 30-kDa protein attenuate virulence in vivo. Having demon-
strated the stability and wild-type growth of VUSS0 (His6398/
Pro94), VUSS1 (Tyr6398/Pro94), VUSS2 (His6398/Leu94),
and VUSS3 (Tyr6398/Leu94), the virulence of the viruses was
determined by intracranial inoculation of C57BL/6 mice in
direct comparison with a virulent wild-type recombinant
MHV-A59 (RA59). Virulence assays were carried out as de-
scribed in Materials and Methods, and log10 LD50 values were
calculated for each virus (Table 2). RA59 was virulent follow-
ing intracranial inoculation, causing clinical disease and mor-
tality in mice, with an LD50 of 3.8 log10, consistent with previ-
ous published virulence measurements with this virus (27, 33).
In contrast, VUSS0 (His6398/Pro94) caused no death in inoc-
ulated mice and thus had an LD50 of 5.3 log10. The VUSS2
virus (His6398/Leu94) was also avirulent (LD50  5.3 log10n),
indicating that the single Tyr6398His substitution was sufficient
to eliminate virulence and raising the question of whether the
substitution at Leu94 had any role in loss of virulence. When
VUSS1 (Tyr6398/Pro94) was analyzed, it had an LD50 of 4.8
log10, demonstrating that it had an independent effect on vir-
ulence. To determine if repair of Tyr6398 and Leu94 restored
virulence, VUSS3 (Tyr6398/Leu94) was analyzed and demon-
strated virulence equivalent to RA59 (LD50 3.8 log10), indicat-
ing that repair of Tyr6398 and Leu94 was necessary and suffi-
cient to restore virulence following intracranial inoculation of
mice.
Attenuated MHV viruses have reduced titers in mouse
brains and livers at day 5 following intracranial inoculation.
To determine if the mutant viruses were replicating in vivo, 10
mice per virus were inoculated intracranially with 5 103 PFU
of VUSS0, VUSS2, VUSS3, and RA59. Mice were sacrificed
on days 5 and 7 postinfection (five each on days 5 and 7 per
virus), the brains were collected and homogenized, and virus
was titered from clarified brain homogenates. In previous stud-
ies of virulent A59 strains following intracranial inoculation,
peak replication occurs during the first week postinfection,
peaking at day 5. Virus is usually not measurable by day 7, as
was the case for all viruses in this study, with no measured virus
titers by day 7 (not shown). At day 5 postinfection, RA59 and
VUSS3 viruses had similar titers of 2.1  104 and 3.1  104
PFU per g of brain tissue, respectively (Fig. 5). In contrast, the
attenuated VUSS0 and VUSS2 viruses had much less measur-
able virus at 5 days postinfection, with mean titers of 2.8  102
and 1.6 102 PFU/g of brain tissue, respectively. Virus from
brains of mice infected with VUSS0 and VUSS2 could only be
measured in nondiluted, clarified homogenates, but the results
FIG. 4. Growth analysis of mutant viruses. Flasks of DBT cells (107
cells) were infected in duplicate with wild-type A59 (), VUSS0 (■),
VUSS1 (Œ), VUSS2 (X), and VUSS3 (F). (A) Multiplicity of infection
of 5 PFU/cell. (B) Multiplicity of infection of 0.01 PFU/cell. Medium
supernatant samples were obtained at 0, 4, 8, 12, 16, 24, and 32 h
postinfection The plotted points represent the average of the viral titer
determined by plaque assay for duplicate samples at each time point
from two replicate infections.
TABLE 2. Virulence in mice for wild-type RA59, corrected
VUSS3, and mutants VUSS0, VUSS1, and VUSS2
Virus Amino acid(p59/ORF2a)
Log10 LD50 (PFU)
Trial 1 Trial 2
RA59 Tyr/Leu 3.80
VUSS0 His/Pro 5.30 5.30
VUSS1 Tyr/Pro 4.67 4.80
VUSS2 His/Leu 5.30 5.30
VUSS3 Tyr/Leu 3.80 3.80
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were reproducible in replicate assays for both viruses. Thus,
the loss of virulence of VUSS0 and VUSS2 was associated with
decreased virus in the brains of infected mice at 5 days
postinfection
MHV-A59 infection by an intracranial route also results in
replication in the liver and hepatitis (27). To determine
whether virus replication in the liver was detectable for mutant
viruses, the livers from the same mice used to obtain brain
titers at day 5 were homogenized and analyzed by plaque assay
on DBT cells. For VUSS3, virus was detectable in four of five
mice, with mean titers of 1.74  103 PFU per g of liver for the
four mice with detectable virus. In contrast, for VUSS0 and
VUSS2, no virus plaques were observed in either diluted or
undiluted clarified homogenates. Whether replication was not
occurring, was at such a low level as to be below limits of
detection, or was rapidly cleared from the liver, the result
indicates a replication defect for VUSS0 and VUSS2 in the
liver as well as in the brain.
Retention and reversion of attenuating mutations in vivo.
Since the amount of virus detected in the brains of mice in-
fected with VUSS0 and VUSS2 was reduced, and since the
mouse brain virus titers suggested significant variation in rep-
lication of specific viruses in different mice, we next deter-
mined if there was evidence of pressure for selection of rever-
sion to wild-type sequences Tyr6398 and Leu94. From the
plaque assay used to generate the data in Fig. 5, plaques were
selected and inoculated into 25-cm2 flasks of DBT cells. Total
cellular RNA was harvested when the monolayers were greater
than 80% involved with syncytia, and the RNA was reverse
transcription-PCR sequenced across the 3 kb of the genome
RNA coding sequence for both Tyr6398 and Leu94.
Initially, plaque isolates from each of two mice were se-
quenced for each input virus. The plaque isolates from mice
infected with VUSS3 and RA59 maintained Tyr6398 and
Leu94 in all cases, confirming the stability of the wild-type
residues (Table 3). For both VUSS0 (His6398/Pro94) and
VUSS2 (His6398/Leu94), plaque virus isolates from one
mouse maintained the sequences of the infecting virus ge-
nomes. However, the plaque isolates from a second mouse for
VUSS0 and VUSS2 showed changes at either or both residues.
We therefore sequenced multiple plaque isolates from the
mice demonstrating changes as well as plaque isolates from up
to five total mice for these viruses. For VUSS0, seven plaque
isolates from a total of four mice retained the input His6398/
Pro94 substitutions. However for mouse 4, one plaque isolate
retained the substitutions, while three isolates showed rever-
sion at both residues to wild-type Tyr6398/Leu94, and one
plaque isolate showed partial reversion to Tyr6398/Pro94. For
VUSS2, six plaque isolates from three mice retained the input
residues His6398 and Leu94, while five isolates from one
mouse showed changes at both residues, resulting in Tyr6398
and Pro94. This combination recapitulated that of engineered
VUSS1, which was less virulent than wild-type or VUSS3
(Tyr6398/Leu94), but more virulent than the input VUSS2.
While contamination cannot be entirely ruled out, VUSS1 was
not included in this experiment, and all animals were inocu-
lated with the same vial of VUSS2.
These results demonstrate that for the majority of infected
mice, the input sequence and amino acids were retained, but
reversion of either or both single-nucleotide coding mutations
FIG. 5. Virus titers in brain tissue of infected mice, sacrificed at 5
days postinfection. Viral titers of clarified brain homogenates (five
mice/virus) were determined by plaque assay in DBT cells. The titer
for each sample was determined in two separate plaque assays, with
each point the average of two measurements and normalized for brain
mass. Means for five mice are indicated. Titers for VUSS0 and VUSS2
were reproducible in separate plaque assays, with plaques detected
only in undiluted specimens.
TABLE 3. Amino acid sequences of virus plaque isolates from
mouse brains infected with RA59, VUSS3, VUSS0, and VUSS2a
Strain and
mouse no. Plaque isolate(s)
ORF1b p59-nsp14
aa6398
ORF2a 30-kDa
aa94
RA59 TYR LEU
Mouse 3 1 Tyr Leu
Mouse 4 1 Tyr Leu
VUSS3 TYR LEU
Mouse 2 1 Tyr Leu
Mouse 3 1 Tyr Leu
VUSS0 HIS PRO
Mouse 1 1, 3, 4 (Tyr) (Leu)
Mouse 1 5 (Tyr) Pro
Mouse 1 6 His Pro
Mouse 2 1 His Pro
Mouse 3 1, 2 His Pro
Mouse 4 1, 2 His Pro
Mouse 5 1, 2 His Pro
VUSS2 HIS LEU
Mouse 1 1, 2 His Leu
Mouse 2 1, 2 His Leu
Mouse 4 1, 3, 4, 5, 6 (Tyr) (Pro)
Mouse 5 1 His Leu
a Input sequence is indicated by bold capitals. Changes from input sequence
are indicated by parentheses. VUSS0 mouse 5 isolates both contained an A to C
mutation coding Asp to Ala change at aa 53 in ORF2a 30-kDa protein.
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in ORF 1b p59 and ORF 2a protein can occur during infection
of mice, with evidence for selective pressure for more virulent
wild-type or partial wild-type protein sequences. These results
also support the conclusion that active replication of the at-
tenuated mutants is occurring, since replication is required for
generation and selection of changes, particularly of two inde-
pendent mutations.
DISCUSSION
In this study we demonstrate that two single-nucleotide mutations that result
in amino acid substitutions in the ORF 1b p59-nsp14 protein and the ORF 2a
30-kDa protein of MHV-A59 attenuate virulence in mice while having no mea-
surable effect on virus replication in culture. By restoring the consensus wild-type
sequences individually and in combination, we confirmed that the mutations are
both independently and in combination attenuating in mice, although their
phenotypes in DBT cell culture are indistinguishable from wild type MHV-A59.
One of the mutations, encoding a Leu94Pro substitution in the ORF 2a 30-kDa
protein, was only partially attenuating in the absence of any other changes. The
second mutation, encoding a Tyr6398His substitution in the ORF 1b p59-nsp14
replicase protein, was completely attenuating independently or in combination
with the first mutation. These results show that MHV genome RNA transcribed
from an in vitro-assembled full-length cDNA can direct the synthesis of virus that
has wild-type replication in culture and virulence in mice. The results further
demonstrate the ability to use reverse genetic approaches to determine the
contribution of specific proteins and residues to replication and virulence.
Identification of attenuating mutations and restoration of
virulence of in vitro-assembled recombinant MHV. The dis-
covery of two mutations in genome fragment F that attenuated
virulence in mice but caused no detectable phenotype in cell
culture was surprising. Since the sequence differed from that of
the original fragment F at both nucleotides, we proposed that
the mutations were selected for during propagation of the
genome fragment F in the pTopo vector in E. coli. When we
attempted to repair the fragment F cDNA to encode the con-
sensus wild-type Tyr6398 and Leu94 residues by site-directed
mutagenesis and propagation in E. coli, fragment F cDNA
encoding His6398/Pro94 was recovered, supporting the conclu-
sion that toxicity or other deleterious effects of the wild-type
sequences in E. coli may have selected for the mutations.
We therefore subcloned fragment F into the pSMART-
LCAmp vector (Lucigen), which subsequently allowed repair
of the mutations and has remained stable during propagation
in E. coli. The sequencing of the fragments also demonstrated
that cloned genome fragments A, B, C, D, E, and G (pMH54)
are stable during propagation in E. coli, with no evidence of
deletion, truncation, or deleterious mutations. In addition, the
wild-type replication and virulence of VUSS3 containing the
corrected fragment F confirm that the strategy for assembly of
cloned fragments, in vitro transcription of genome RNA, and
electroporation of RNA into cells is clearly able to generate
stably virulent virus. Thus, it will be possible to engineer
changes in single fragments while maintaining a highly stable
sequence in other fragments. It will also be possible, as we have
previously demonstrated, to directly compare sequences from
rescued viruses with the fragments specifically used for assem-
bly and thereby identify reversions or compensating mutations
introduced by the virus. The ability to reintroduce the original
mutation and any candidate compensating mutations will allow
rapid testing and confirmation of the changes and their rele-
vance to replication and virulence. Finally, the results provide
a basis for comparison with other viruses, both natural variants
and viruses derived by any reverse genetic approaches, by pro-
viding the completely characterized sequence of a stably
cloned MHV-A59 genome of a virus with wild-type replication
in culture and virulence in vivo.
The observed outcome of intracranial infection in mice with
the mutant or partially corrected viruses was greatly reduced
virulence, as measured by the LD50. This global decrease in
virulence could have resulted from decreased replication, de-
creased virulence independent of replication, or altered im-
mune response. Host cell proteins have been shown to interact
with the genome during viral RNA synthesis (40, 51). MHV
has been shown to utilize mitogen-activated protein kinase
signaling in the cell and eIF4E phosphorylation to promote
virus production (1). MHV also utilizes components of cellular
autophagy during replication (34). Furthermore, it has been
reported that MHV specifically suppresses the translation of
some cellular mRNAs but not others (46). Thus, the ORF 1b
p59-nsp14 and/or ORF 2a 30-kDa proteins might normally
interact with or modulate the expression of host cellular factors
required for viral replication in the mouse, leading to a reduc-
tion of viral replication.
Alternatively, the proteins might be involved in modulating
the host immune response. Differences in encephalitis disease
severity for different strains of MHV have been associated with
the differential regulation of cytokines and the innate immune
response stimulated by the viruses (31, 35). Hence, it is possi-
ble that in the presence of the mutant proteins, cytokines or
other antiviral components are differentially activated, leading
to an altered immune response.
The titer of infectious virus in the brains and livers at day 5
postinfection was reduced or undetectable in mice infected
with VUSS0 and VUSS2 compared to the corrected VUSS3.
However, the detection of infectious virus in brains at day 5,
along with the reversion or partial reversion to the wild-type
sequences observed for both VUSS0 and VUSS2, demon-
strates that replication was occurring and that there was pres-
sure for selection of more fit virus. Further, both VUSS0 and
VUSS2 demonstrated wild-type growth in culture even at a low
multiplicity of infection, indicating that the viral machinery
necessary for entry, replication, assembly, and release is intact.
Thus, if the observed decrease in virulence is due to replication
defects, they would likely be due to cell-specific requirements
that are not present in the murine DBT or hamster BHK cell
lines. This in turn would suggest that the ORF 1b p59-nsp14
and ORF 2a 30-kDa proteins may function during interactions
with specific cell types. Whether replication, pathogenesis, or
both are directly affected, it is clear that the virus is specifically
attenuated in vivo by changes in the proteins that appear to be
dispensable for in vitro replication.
ORF 2a 30-kDa and ORF 1b p59-nsp14 proteins in replica-
tion and virulence. The ORF 2a 30-kDa protein is one of a
group of group-specific proteins (2a, 4, and 5a) that have been
reported to be nonessential for replication in culture (29, 37,
47, 48). The small ORF 7-encoded group I coronavirus-specific
protein of the porcine coronavirus transmissible gastroenteritis
virus is nonessential for replication but does influence in vivo
replication and virulence (30). For MHV, no direct function in
pathogenesis has been established for the group-specific pro-
teins. A recombinant MHV lacking ORF s 2a, 4, and 5a has
been shown to be avirulent in mice, but this virus is also
defective for replication in vitro, making it difficult to interpret
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the in vivo attenuation (10). Furthermore, a recombinant
MHV-JHM lacking expression of ORF 4 appeared to display
neurovirulence equal to wild-type JHM (29).
The MHV ORF 2a 30-kDa protein is only found among
group 2 coronaviruses. The wild-type Leu94 is completely con-
served among group 2 viruses that possess the ORF 2a protein.
While this protein also has no known function, it has been
reported to be a nonstructural protein that is cytosolic and
non-membrane associated (3, 52). A similarity search pro-
duced an alignment of the protein to three consensus sequence
elements for GTP and ATP nucleotide binding (25). The
Leu94 amino acid residue aligns with a hydrophobic consensus
sequence element. Another more recent bioinformatics anal-
ysis has predicted the protein to be a cyclic phosphodiesterase
based on limited similarity to the catalytic motifs of two do-
mains adjacent to the nucleotide binding elements (43). While
none of these functions has been experimentally confirmed,
our result showing partial attenuation of virulence with a single
amino acid substitution and restoration of virulence following
repair of the mutation strongly suggests a role for direct func-
tions or virus cell interactions critical for virus survival and
disease in the host.
Comparison of multiple coronaviruses indicates that the rep-
licase gene may express both group-specific proteins (nsp1-p28
and nsp2-p65 of group 2 viruses), as well as moderately to
highly conserved orthologs of MHV nsp3-16 in all coronavi-
ruses. This organization and conservation of sequence have
been the basis for concluding that the nsp3 through nsp16
proteins serve critical roles in the replication of coronaviruses,
a conclusion confirmed for the papain-like proteinase activities
of nsp3, the 3C-like proteinase activity of nsp4, and the heli-
case activities of nsp13 in addition to the highly likely but as yet
unconfirmed polymerase activity of nsp12. More recently,
RNA processing activities have been predicted for nsps 14, 15,
and 16. nsp14-p59 has highly conserved orthologs in all coro-
naviruses that have been predicted to be an exoribonuclease of
the DEDD superfamily (43). This prediction is based on pri-
mary amino acid sequence identity of three motifs containing,
among other features, the putative catalytic aspartic and glu-
tamic acid residues necessary for the exonuclease activity.
It is unknown what role the predicted p59-nsp14-exoribo-
nuclease might have in the context of viral replication. The
Tyr6398His substitution identified in this study was 140 amino
acids downstream of the last predicted exoribonuclease cata-
lytic motif. It is possible that an amino acid substitution distal
to the putative active motifs could still alter or abolish the core
protein function. If so, this would suggest that protein function
of nsp14 is not required for MHV replication in culture. How-
ever, experiments in our laboratory with substitutions and de-
letions at other residues of p59-nsp14 suggest that the protein
is likely required for replication (Sperry et al., unpublished
results). Alternatively, ORF 1b p59-nsp14 may serve more
than one role in replication and pathogenesis. The nsp14 or-
thologs of all sequenced coronaviruses have a high degree of
overall identity and similarity, and more specifically, the
Tyr6398 residue is 100% conserved in all coronaviruses se-
quenced to date. Experiments in progress will define if other
substitutions at Tyr6398 and across the putative catalytic and
zinc finger residues of nsp14 allow recovery of viable virus with
wild-type replication or demonstrate various degrees of im-
pairment or an absolute requirement for the intact protein.
Finally, the conservation of identified residues will make it
possible to determine if similar substitutions are attenuating in
other coronaviruses. The recent establishment of a reverse
genetic system for severe acute respiratory syndrome corona-
virus should make it possible to test whether substitutions at
the conserved Tyr residues allow wild-type growth in culture
and attenuation in animal models. If so, this could represent an
approach for stable attenuation of severe acute respiratory
syndrome coronavirus virulence by combining this powerfully
attenuating mutation with other independently attenuating al-
leles across the genome
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